Clinical trials: Obese, Otherwise Healthy Volunteers
Insulin Resistance
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance
This study will evaluate the safety and tolerability profile of BFKB8488A following subcutaneous (SC) administration in overweight and obese participants (body mass index [BMI] greater than [>] 27 to less than or equal to [</=]…
- Trial name
- NCT02593331
- Testing
- BFKB8488A
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers
A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2 weeks of dosing of PF-06427878 in…
- Trial name
- NCT02855177
- Testing
- PF-06427878
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers
The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of increasing doses of canagliflozin (JNJ-28431754) in healthy obese…
- Trial name
- NCT01756404
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight
A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics following a single oral dose.
- Trial name
- NCT00799006
- Testing
- PF-04620110
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Participants, Obese But Otherwise Healthy Participants
Fructose Intestinal Gluconeogenesis
This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from…
- Trial name
- FIG (NCT07209202)
- Testing
- High fructose meal, Low fructose meal, 13C labeled fructose, oral
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Touro University, California
Obesity
Effects of Repeat Dosing of GSK1521498
The overall purpose of this study is to see whether the drug is safe and well tolerated when given to overweight or obese but otherwise healthy volunteers for 10 days.
- Trial name
- NCT00976105
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity
Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers
The purpose of this study is to determine whether CP-866,087 is effective in the weight loss of overweight patients.
- Trial name
- NCT00479492
- Testing
- CP-866,087
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Pfizer
Healthy
A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110.
- Trial name
- NCT01146327
- Testing
- PF-04620110
- Where
- 2 sites in Belgium, Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pregnant Women, Gestational Diabetes
Physical Acvitiy in Pregnancy
The goal of this observational study is to learn how a physically active lifestyle during pregnancy affects placental development and function.
- Conditions
- Pregnant Women, Gestational Diabetes, Obese But Otherwise Healthy Participants, Overweight (BMI > 25)
- Trial name
- NCT07356180
- Testing
- Pregnancy Physical Activity Questionnaire (PPAQ)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Maryland, Baltimore
Overweight, Obesity
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg.
- Trial name
- NCT06564441
- Testing
- Survodutide, Bupropion, Caffeine
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer
A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)
Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral…
- Trial name
- NCT01018823
- Testing
- Ertugliflozin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Metabolism and Nutrition Disorder, Obesity
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects
This trial is conducted in the United States of America. The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses and multiple doses of…
- Trial name
- NCT02568306
- Testing
- NNC0165-1562
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obese But Otherwise Healthy Participants
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will…
- Trial name
- CANYON-1 (NCT07310901)
- Testing
- CRB-913
- Where
- 15 sites in United States
- Volunteers
- 254 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Healthy
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
This trial is intended to examine the basic pharmacokinetics of BI 456906 and total [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in…
- Trial name
- NCT05421338
- Testing
- BI 456906 (C-14)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects
The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of PF-04620110 as a modified-release formulation.
- Trial name
- NCT01474941
- Where
- Belgium
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects
The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese
- Trial name
- NCT00148382
- Testing
- ATL-962
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Alizyme
Healthy
A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants and Otherwise Healthy Participants With Obesity
The goal of this clinical trial is to assess the safety, tolerability and blood levels following a single dose or after multiple doses of CK-0045 given subcutaneously to healthy participants or otherwise healthy participants with…
- Trial name
- NCT05712876
- Testing
- CK-0045
- Where
- Belgium
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Cytoki Pharma
Healthy Volunteers;, Obese, Otherwise Healthy Volunteers
A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of a predefined dose range of co-administered Baclofen and Memantine in non-obese (Part A) and obese (Part B), otherwise healthy subjects.
- Trial name
- NCT02001584
- Testing
- Baclofen, Memantine
- Where
- United Kingdom
- Sponsor
- Gedeon Richter Plc.
Healthy
A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects
This study is designed to compare the pharmacokinetics of three different formulations of Pf-04937319
- Trial name
- NCT01513928
- Testing
- Pf-04937319
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants.
- Trial name
- NCT04839393
- Testing
- PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer